menu
    • menu
    [{"orgOrder":0,"company":"VectorY","sponsor":"Annogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Annogen","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Annogen"},{"orgOrder":0,"company":"VectorY","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Forbion"},{"orgOrder":0,"company":"VectorY","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ MRL Ventures Fund","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ MRL Ventures Fund"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"UMC Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ UMC Utrecht","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ UMC Utrecht"},{"orgOrder":0,"company":"VectorY","sponsor":"University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ University Medical Center"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV-VecTabs","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Wageningen University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Wageningen University","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Wageningen University"}]

    Find Clinical Drug Pipeline Developments & Deals by VectorY

    Menu

    VectorY

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : University Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            UMC Utrecht and VectorY collaborate to identify biomarkers of ALS in new study

                            Details : The collaboration aims to support VectorY’s lead program, VTx-002, which is being evaluated in the early-stage clinical trial studies for the treatment of ALS.

                            Product Name : VTx-002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 18, 2024

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : University Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : UMC Utrecht

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study

                            Details : VTx-002, a vectorized antibody that selectively clears misfolded and aggregated TDP-43 from the cytoplasm of neuronal cells, is being developed for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : VTx-002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 17, 2024

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : UMC Utrecht

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : MRL Ventures Fund

                            Deal Size : $138.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neu...

                            Details : VectorY will use the proceeds to support the clinical development of VTx-002 (OPL-002), its lead vectorized antibody program targeting TDP-43 for the treatment of amyotrophic lateral sclerosis.

                            Product Name : VTx-002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            November 13, 2023

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : MRL Ventures Fund

                            Deal Size : $138.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Annogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

                            Details : Under the terms of the agreement, VectorY and Annogen will work on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to yield disease-modifying treatments for neurodegenerative...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 19, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Annogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-2...

                            Details : VecTabs, which are secreted- or intracellular-antibody fragments that are AAV-vectorized and delivered to neurons and/or astrocytes, have previously been shown to efficiently target such misfolded proteins (TDP-43) and toxic lipids (oxPL).

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 23, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell T...

                            Details : VTx-002, reduce TDP-43 pathological aggregates for treating ALS, TAR-DNA binding protein-43 is necessary for correct processing and transport of multiple mRNA’s that are essential for neuronal survival.

                            Product Name : VTx-002

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : VTx-002

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-VecTabs

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VectorY Presents New Pre-clinical data at the European Network for the Cure of ALS (ENCALS)

                            Details : The new data demonstrate therapeutic potential and versatility of VectorY’s VecTab platform technology, enabling development of secreted or intracellular antibody fragments that are AAV-VecTabs delivered to neurons and/or astrocytes, in vitro and in vi...

                            Product Name : AAV-VecTabs

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 06, 2022

                            Lead Product(s) : AAV-VecTabs

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : Wageningen University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Wageningen University & Research and VectorY to Jointly Develop Novel Production Technologies for Safer and Mo...

                            Details : The strategy is based on the baculovirus expression system, which is already widely used for vaccine production and uses viruses that can only infect insect cells, the so-called baculoviruses.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 25, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : Wageningen University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed

                            VectorY

                            Netherlands arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Forbion

                            Deal Size : $36.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and...

                            Details : Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Forbion

                            Deal Size : $36.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth